Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 38.06% is in line with its 5-year average of 40.66%, around the middle of its 5-year range (26.06%–56.88%).
As of the fiscal period ended Wednesday, December 31, 2025. 18.71% above its 12-month average of 32.06%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
38.06%
RETURN ON EQUITY (ROE) AVG TTM
32.06%
RETURN ON EQUITY (ROE) AVG 3Y
36.93%
RETURN ON EQUITY (ROE) AVG 5Y
40.66%
RETURN ON EQUITY (ROE) AVG 10Y
39.83%
RETURN ON EQUITY (ROE) AVG 15Y
45.77%
RETURN ON EQUITY (ROE) AVG 20Y
42.95%
CURRENT VS TTM AVG
+18.71%
CURRENT VS 3Y AVG
+3.07%
CURRENT VS 5Y AVG
-6.38%
CURRENT VS 10Y AVG
-4.44%
CURRENT VS 15Y AVG
-16.85%
CURRENT VS 20Y AVG
-11.39%
SECTOR MEDIAN · HEALTHCARE
12.77%
median of 85 covered companies
CURRENT VS SECTOR MEDIAN
+198.04%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
Return on Equity (ROE)
38.06%
TTM Avg
32.06%
3Y Avg
36.93%
5Y Avg
40.66%
Market Cap
$358.76B
Return on Equity (ROE)
13.51%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
Market Cap
$369.34B
Return on Equity (ROE)
7.57%
TTM Avg
35.83%
3Y Avg
26.05%
5Y Avg
27.71%
Market Cap
$455.87B
Return on Equity (ROE)
-129.24%
TTM Avg
-0.29%
3Y Avg
28.74%
5Y Avg
37.53%
Market Cap
$255.15B
Return on Equity (ROE)
20.79%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$235.85B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$234.38B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$205.42B
Return on Equity (ROE)
53.50%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$193.04B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 38.06% | 32.06% | 36.93% | 40.66% |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 13.51% | 14.18% | 19.86% | 21.18% |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 7.57% | 35.83% | 26.05% | 27.71% |
| AbbVie Inc. (ABBV)vs › | $455.87B | -129.24% | -0.29% | 28.74% | 37.53% |
| AstraZeneca PLC (AZN)vs › | $255.15B | 20.79% | 19.16% | 15.60% | 13.86% |
| Amgen Inc. (AMGN)vs › | $235.85B | 74.80% | 79.33% | 111.35% | 101.76% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 13.25% | 12.70% | 13.51% | 15.24% |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 53.50% | 61.58% | 67.05% | 123.42% |
| Abbott Laboratories (ABT)vs › | $193.04B | 10.61% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | -27.39% | 19.98% | 21.60% | 19.44% |
ROE
38.1%
ROA
12.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 38.06% |
| 2024-12-31 | 26.06% |
| 2023-12-31 | 39.22% |
| 2022-12-31 | 44.37% |
| 2021-12-31 | 56.88% |
| 2020-12-31 | 39.34% |
| 2019-12-31 | 41.22% |
| 2018-12-31 | 38.01% |
| 2017-12-31 | 32.65% |
| 2016-12-31 | 40.05% |
| 2015-12-31 | 42.25% |
| 2014-12-31 | 47.65% |
| 2013-12-31 | 57.86% |
| 2012-12-31 | 65.72% |
| 2011-12-31 | 77.25% |
| 2010-12-31 | 91.52% |
| 2009-12-31 | 105.67% |
| 2008-12-31 | 20.16% |
| 2007-12-31 | 21.53% |
| 2006-12-31 | 19.98% |
| 2005-12-31 | 19.27% |
| 2004-12-31 | 23.53% |
| 2003-12-31 | 13.02% |
| 2002-12-31 | -19.35% |
| 2001-12-31 | 12.76% |
| 2000-12-31 | 31.32% |
| 1999-12-31 | 21.38% |
| 1998-12-31 | 20.27% |
